Moderna, Inc. $MRNA Stock: Ritholtz Wealth Management Raises Stake

Ritholtz Wealth Management lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 162.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,001 shares of the company’s stock after acquiring an additional 5,575 shares during the quarter. Ritholtz Wealth Management’s holdings in Moderna were worth $1,733,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Western Pacific Wealth Management LP bought a new position in Moderna in the third quarter worth approximately $29,000. Allied Private Wealth LLC purchased a new position in Moderna during the 2nd quarter worth $30,000. Next Level Wealth Planning LLC purchased a new position in Moderna during the 3rd quarter worth $34,000. Archer Investment Corp purchased a new position in Moderna during the 2nd quarter worth $36,000. Finally, Ramsey Quantitative Systems bought a new stake in Moderna during the 3rd quarter valued at $40,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,251 shares of company stock worth $33,875,904 over the last 90 days. Company insiders own 10.80% of the company’s stock.

More Moderna News

Investors following MRNA have been watching these news items:

  • Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
  • Neutral Sentiment: Moderna is scheduled to join the MSCI World Index in November, which could broaden its investor reach. It also reported peer-reviewed real-world data on its mNEXSPIKE COVID-19 vaccine in older adults; the reports provided limited detail on the potential commercial impact. Article
  • Negative Sentiment: Investors are concerned about roughly $4 billion in planned 2027 cash costs, much of it tied to pipeline investment, while visibility into future revenue growth remains limited. Coverage also noted that the 2026 revenue outlook may fall short of analyst expectations, tempering the more optimistic growth forecast. Article

Analyst Upgrades and Downgrades

MRNA has been the subject of several research reports. UBS Group reiterated a “neutral” rating on shares of Moderna in a report on Tuesday, September 22nd. Deutsche Bank assumed coverage on Moderna in a research report on Friday, August 28th. They set a “hold” rating and a $125.00 price target on the stock. Barclays raised their price target on Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research note on Monday, August 24th. CLSA upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. Finally, Rothschild & Co Redburn downgraded Moderna from a “neutral” rating to a “sell” rating and lifted their price objective for the company from $40.00 to $81.00 in a report on Thursday, September 3rd. Six equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and an average price target of $113.75.

Check Out Our Latest Research Report on MRNA

Moderna Price Performance

NASDAQ MRNA opened at $223.37 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. The firm’s 50 day moving average price is $201.67 and its 200-day moving average price is $96.41. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $280.80. The company has a market cap of $90.38 billion, a PE ratio of -31.46 and a beta of 1.16.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $1.48. The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. Moderna’s revenue was up 29.2% compared to the same quarter last year. During the same period last year, the company posted ($0.51) earnings per share. Sell-side analysts forecast that Moderna, Inc. will post -5.14 EPS for the current fiscal year.

Moderna Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Recommended Stories

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.